Granules India Limited has informed the Exchange about General Updates
GRANULES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.7 pts less than Nifty Smallcap 250 and 0.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Granules India informed the exchanges that the US FDA conducted a Pre-Approval Inspection (PAI) at the facility of its wholly owned subsidiary, Granules Life Sciences Private Limited, located in Shamirpet Mandal, Hyderabad, from July 28 to August 01, 2025. The inspection concluded with one Form 483 observation, which the company described as procedural in nature. Granules Life Sciences is engaged in manufacturing Pharmaceutical Formulation Intermediates (PFI) and Finished Dosages. The company stated it will respond to the observation within the stipulated time frame. This disclosure was made under SEBI Listing Regulations.
A single procedural 483 observation is generally considered minor and is common in FDA inspections, suggesting limited near-term risk to operations. However, investors should watch for the company's response and any follow-up actions, as repeated observations could affect future product approvals for the subsidiary.